首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1160818

肿瘤溶解性病毒免疫疗法的全球市场、临床实验的考察 (2028年)

Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight 2028

出版日期: 2022年11月01日 | 出版商:

KuicK Research | 英文 | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球癌症免疫疗法市场，包含广泛的有效利用领域，其中，肿瘤溶解性病毒免疫疗法，在市场整体发展中也肩负着重要角色。研究人员们，导入宿主细胞为目标的病毒的优点，成功修正基本的免疫疗法策略。超越宿主细胞采用的病毒出色的能力，癌症治疗药引进病毒治疗，提供了肿瘤学市场长期缺乏的大量机会。今后，如果对广泛种类的癌症肿瘤溶解性病毒治疗受到承认，製药产业强化，销售额将到达任何癌症治疗药的空前记录。

本报告提供全球肿瘤溶解性病毒免疫疗法的市场、临床实验趋势相关分析，产品概要和主要用途，整体市场规模趋势预测，现在临床实验中的产品的概要 (共180种以上)，主要产品的可得性、剂量、价格水准预测，临床实验的整体发展情形，近来的资本交易的动向，主要企业的简介等彙整资讯，为您概述为以下内容。

Global cancer immunotherapy market encompasses broad range of applications, in which oncolytic virus immunotherapy is playing a vital role in the overall development. The therapy involves a very basic thread of using virus for targeting cancer cells and to harness the natural as well as destructive power of the immune system against the cancer cells. In a very short period of time, the clinical outcome associated with the therapy has laid down foundation for the over-achieving future of the therapy. The therapy market is estimated to get recognized as a necessity in the overall cancer therapeutics market where old and traditional therapies available are not successful in declining the increasing mortality rate across the globe.

Researchers have been successful in modifying the basic immunotherapy strategy by introducing the benefits of virus in targeting the host cells. Beyond the excellent capacity of the virus to get incorporated into the host cell, the therapeutic introduction of virus in the cancer therapeutics is providing enormous amounts of opportunities which were somehow lacking in the overall cancer therapeutics market for prolonged period of time. The future approval of the oncolytic virus therapy against wide range of cancer types is believed to strengthen the pharmaceutical industry to reach the revenue sales that have not been recorded for any of the cancer therapy drugs.

The strong link of the therapy with clinical pipeline and the future timeframe which is about to justify the applications of the therapy are observed to over-come the challenges which the researchers have been facing in terms of resistance development, off-targeting and adverse side effects. Amid the growth of other cancer therapies in the cancer therapeutics market, oncolytic virus therapy soon is going to deliver significant revolution and growth. The unimaginable applications of the therapy and the orientation of the government bodies towards expanding the clinical trial market of the same is estimated to develop the market as a dominant one for millions of patients who haven't received any benefits from the available therapies. The entry of the oncolytic virus therapy into the market horizon is estimated to provide enormous healthcare opportunities to the patients who have been struggling with cancer for a prolonged period of time.

As per “Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight 2028” report findings, the overall appreciation that the therapy has achieved in such shorter time period is poised to incline the therapy towards substantial growth. In the coming time period, the therapy market is believed to deliver promising trends and opportunities for the researchers working in different bio-pharmaceutical companies and research centers, with hundreds of driving forces driving the market through various complications. On the regulatory side, the legislations of developed pharmaceutical countries are also inclining towards boosting the researchers to expand the market applications and drive the competition in the right direction, where appropriate funds for the clinical research activities is acting as the catalyst for the therapy. The unlimited applications found within the therapy and the clinical platform for the same is estimated to move the therapy towards success at an unprecedented rate in the coming years.

1. Introduction to Oncolytic Virus: Trail From Genesis To Biogenetics

2. Primer of Virotherapy in Malignancies

2.1. Oncolytic Viruses Towards Cancer
2.2. Approaches for Targeting Tumor Cells
2.3. Viral Oncolysis Mechanism of Action

3. Oncolytic Viruses Immunotherapy Overview

3.1. Stimulation of Antitumor Immune Responses
3.2. Oncolytic Viruses as Cancer Vaccines

4. Potential Oncolytic Virus Immunotherapy for Cancers

4.1. Breast Cancer
4.2. Lung Cancer
4.3. Prostate Cancer
4.4. Melanoma
4.5. Brain Tumor
4.6. Blood Cancer
4.7. Colorectal Cancer
4.8. Bladder Cancer
4.9. Pancreatic Cancer
4.10. Head & Neck Cancer

5. Global Oncolytic Virus Immunotherapy Therapy Market Overview

5.1. Preface Towards Oncolytic Virus Arcade
5.2. Market Aspects of Approved Oncolytic Viruses

6. Imlygic (Talimogene laherparepvec): Clinical & Pricing Insight

6.1. Clinical Overview
6.2. Availability, Dosage & Price Analysis

7. Oncorine (H101): Clinical & Pricing Insight

7.1. Clinical Overview
7.2. Availability, Dosage & Price Analysis

8. Delytact (DS 1647): Clinical & Pricing Insight

8.1. Clinical Overview
8.2. Availability, Dosage & Price Analysis

9. Global Oncolytic Virus Immunotherapy Clinical Pipeline Overview

9.1. By Phase
9.2. By Company
9.3. By Country
9.4. By Indication
9.5. By Patient Segment

10. Global Oncolytic Viruses Clinical Pipeline By Company, Indication & Phase

10.1. Research
10.2. Preclinical
10.3. Phase-I
10.4. Phase-I/II
10.5. Phase-II
10.6. Phase-III
10.7. Registered

11. Strategic Partnerships, Collaborations, Mergers & Acquisitions to Advance the Oncolytic Virus Therapy Market

11.1. Estrella Biopharma Signs Deal To Merge With Blank Check Company
11.2. ABL & Imugene Announce Partnership to Advance Oncolytic Virus Candidates Into Late Clinical Trial Phase
11.3. TILT Biotherapeutics & Merck to Undergo Clinical Trial Collaboration for Refractory Non-Small Cell Lung Cancer
11.4. Virogin Biotech & MD Anderson Announce Strategic Collaboration For Treating Advance Cancers
11.5. ABL Signs Pact With KaliVir On Oncolytic Viruses
11.6. Targovax Announces Clinical Collaboration With Agenus For Melanoma Trial
11.7. KaliVir Announces Exclusive Agreement With Roche For Developing Novel Oncolytic Viruses
11.8. ImmVira & Roche Enter Cooperation Agreement For Evaluating Novel Combination For Cancer Therapy
11.9. Calidi & Edoc Agree On Merger To Revolutionize Oncolytic Viral Therapies
11.10. Synthetic Biologics Completes Acquisition of VCN Biosciences
11.11. VacV Biotherapeutics Exits Stealth With $3 Million Investment
11.12. Targovax Enters Research Collaboration With Karolinska Institutet Professor
11.13. Transgene and PersonGen To Collaborate To Evaluate New Combination Therapy Against Solid Tumors
11.14. Lokon Pharma Initiates Collaboration With To Develop Novel Cancer Therapeutics
11.15. Bionaut Labs and Candel Therapeutics Announce Collaboration For Novel Targeting Mechanism For Oncolytic Virus Delivery
11.16. Imugene & Eureka Announce Strategic Collaboration to Accelerate Oncolytic Virus and T-Cell Therapy Combination
11.17. CG Oncology Enters Into Clinical Trial Collaboration With Roche For Novel Oncolytic Immunotherapy Combination
11.18. Imugene Enters Into Exclusive Strategic Partnership With Celularity To Develop Novel Combination For Treating Solid Tumors

12. Global Oncolytic Virus Immunotherapy Market Dynamics

12.1. Favorable Market Parameters
12.2. Growth Inhibitors

13. Global Oncolytic Virus Immunotherapy Market Future Outlook

14. Competitive Landscape

14.1. AdCure Bio
14.2. Beijing SyngenTech
14.3. BioVex Inc.
14.4. Calidi Biotherapeutics
14.5. Genelux Corporation
14.6. Immvira Pharma
14.7. Jennerex Biotherapeutics
14.8. KaliVir
14.9. Lokon Pharma
14.10. Merck
14.11. Oncolys BioPharma
14.12. Oncorus
14.13. PsiOxus Therapeutics
14.14. Seneca Therapeutics
14.15. Shanghai Sunway Biotech
14.16. Takara Bio
14.17. Targovax
14.18. TILT Biotherapeutics
14.19. Transgene
14.20. Virogin Biotech

简介目录图表

List of Figures

Figure 1-1: Demonstration of Categorization of Oncolytic Viruses
Figure 1-2: Illustration of Major Events in Clinical Virotherapy
Figure 2-1: Potential Advantages of Oncolytic Viruses over Conventional Therapies
Figure 2-2: The Diagrammatic Representation of Entry of Virions into Cancerous cells
Figure 2-3: Route of Anti-tumoral Efficacy of Oncolytic Viruses
Figure 2-4: Mechanism of Tumor Destruction by Oncolytic Viruses
Figure 2-5: Categorization Followed by Oncolytic Viruses for Tumor Selectivity
Figure 3-1: Demonstration of Phases of Immune Responses Elicited by the Oncolytic Viruses
Figure 3 2: Categorization of Oncolytic Viruses over the Basis of their Behavior
Figure 3 3: Diagrammatic Representation of Oncolysis Shown by Reovirus
Figure 3 4: Mechanism of Oncolytic Behavior of Adenoviruses
Figure 4-1: Selectively Killing of Prostate Cancer Cells by Oncolytic M-Protein Strains of VSV
Figure 4-2: Proposed Treatment of Oncolytic Viruses for Hematological Malignancies
Figure 5-1: Global - Oncolytic Virus Immunotherapy Market Opportunity (US$ Million), 2021 -2028
Figure 6-1: Imlygic - US Patent Expiration Year
Figure 6-2: Imlygic - Price of 1 Million PUF/ml & 100 Million PUF/ml Injectable Suspension (US$), November'2022
Figure 6-3: Imlygic - Dose for Initial Treatment Cycle & Subsequent Treatment Cycle (Million PFU/ ml), November'2022
Figure 6-4: Imlygic - Duration of Initial & Subsequent Treatment Cycle (weeks), November'2022
Figure 6-5: Imlygic - Average Price of Initial Treatment Cycle & Each Subsequent Treatment Cycle (US$), November'2022
Figure 6-6: Imlygic - Volume Administered by Size of Lesion (ml), November'2022
Figure 7-1: Oncorine - Cost of Single Dose & Single Treatment Course (US$), September'2020
Figure 7-2: Oncorine - Duration of Treatment Cycle by Type of Cancer (Days), November'2022
Figure 8-1: Delytact - Initial & Present Price (US$), November'2022
Figure 8-2: Delytact - Designations
Figure 8-3: Japan - Malignant Gliomas Incidences, 2022-2026
Figure 9-1: Oncolytic Virus Immunotherapy Clinical Trials by Phase (Numbers), 2022 till 2028
Figure 9-2: Global - Oncolytic Virus Immunotherapy Clinical Trials by Company (Numbers), 2022 till 2028
Figure 9-3: Global - Oncolytic Virus Immunotherapy Clinical Trials by Country (Numbers), 2022 till 2028
Figure 9-4: Global - Oncolytic Virus Immunotherapy Clinical Trials by Indication (Numbers), 2022 till 2028
Figure 9-5: Global - Oncolytic Virus Immunotherapy Clinical Trials by Patient Segment (Numbers), 2022 till 2028
Figure 12-1: Major Drivers for the Oncolytic Virus Therapies
Figure 12-2: Major Challenges Faced by Oncolytic Viral Therapies

02-2729-4219

+886-2-2729-4219

License/价格

肿瘤溶解性病毒免疫疗法的全球市场、临床实验的考察 (2028年)

Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight 2028

目录

第1章肿瘤溶解性病毒的概要:从创世记到生物遗传学的路程

第2章恶性肿瘤的病毒疗法:概要

第3章肿瘤溶解性病毒免疫疗法概要

第4章肿瘤溶解性病毒免疫疗法对癌症的可能性

第5章全球肿瘤溶解性病毒免疫疗法市场:概要

第6章 Imlygic (Talimogene laherparepvec):临床、价格设定相关考察

第7章 Oncorine (H101):临床、价格设定相关考察

第8章 Delytact (DS 1647):临床、价格设定相关考察

第9章全球肿瘤溶解性病毒免疫疗法的临床实验平台:概要

第10章全球肿瘤溶解性病毒的临床实验平台:各企业、各适应症、各阶段

第11章为了让肿瘤溶解性病毒疗法市场前进的策略性联盟、合作，企业合併、收购 (M&A)

第12章全球肿瘤溶解性病毒免疫疗法市场动态

第13章全球肿瘤溶解性病毒免疫疗法市场未来预测

第14章竞争情形